Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
90%
Progression Free Survival
84%
Renal Cell Carcinoma
80%
Docetaxel
70%
Disease
68%
Overall Survival
63%
Neoplasm
63%
Malignant Neoplasm
50%
Placebo
47%
Castration Resistant Prostate Cancer
45%
Chemotherapy
44%
Clinical Trial
43%
Prostate Specific Antigen
41%
Everolimus
40%
Calcitriol
38%
Kidney Metastasis
38%
Phase II Trials
36%
Imatinib
32%
Adverse Event
31%
Nivolumab
31%
Ipilimumab
31%
Cytotoxic T Lymphocyte Antigen 4
28%
Sorafenib
27%
Gastrointestinal Stromal Tumor
26%
Soft Tissue Sarcoma
26%
Diseases
26%
Gemcitabine
25%
Sunitinib
22%
Diethylstilbestrol
21%
Transdermal
20%
Immunotherapy
19%
Regorafenib
19%
Giant Cell Tumor of Tendon Sheath
19%
Pexidartinib
19%
Diarrhea
19%
Liposarcoma
17%
Kidney Carcinoma
17%
Interleukin 2
17%
Vasculotropin
16%
Neutropenia
16%
Doxorubicin
15%
Methotrexate
14%
Pharmacokinetics
14%
Disease Exacerbation
14%
Prednisone
14%
Taxane
13%
Folinic Acid
12%
Mitoxantrone
12%
Fluorouracil
12%
Keyphrases
Phase II Study
74%
Progression-free Survival
53%
Overall Survival
52%
Rare Tumors
50%
Metastatic Renal Cell Carcinoma (mRCC)
49%
Everolimus
46%
Hormone-sensitive Prostate Cancer
46%
Placebo
46%
Docetaxel
42%
Renal Cell Carcinoma
42%
Partial Response
40%
PD-1 Blockade
40%
Nivolumab
38%
Ipilimumab
38%
Phase II Trial
37%
Basket Trial
35%
Stable Disease
32%
Calcitriol
32%
Southwest Oncology Group
32%
Androgen Deprivation Therapy
29%
Median Progression-free Survival
27%
Confidence Interval
27%
Complete Response
26%
Previously Treated
25%
Adverse Events
25%
High Dose
24%
Placebo-controlled
24%
Clear Cell Renal Cell Carcinoma (ccRCC)
23%
Sunitinib
23%
Anti-CTLA-4
22%
Prostate-specific Antigen
21%
Sorafenib
20%
Phase I Study
20%
Advanced Renal Cell Carcinoma
19%
Pexidartinib
19%
Overall Response Rate
19%
Diarrhea
19%
Response Evaluation Criteria in Solid Tumors (RECIST)
18%
Median Overall Survival
17%
Liposarcoma
17%
Response Rate
17%
Dose-limiting Toxicity
16%
Everest
16%
Interleukin-2
16%
Interferon-α (IFN-α)
16%
Prostate Cancer
15%
Hazard Ratio
14%
Clinical Benefit Rate
14%
Phase II Clinical Trial
14%
Objective Response Rate
14%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
78%
Progression Free Survival
67%
Disease
66%
Rare Tumor
64%
Prostate Cancer
59%
Overall Survival
55%
Neoplasm
48%
Phase II Trials
44%
Nivolumab
40%
Ipilimumab
40%
Clinical Trial
39%
Placebo
36%
Soft Tissue Sarcoma
27%
CTLA-4
27%
Oncology
27%
Androgen Deprivation Therapy
26%
Kidney Metastasis
25%
Everolimus
25%
Sarcoma
25%
Adjuvant Therapy
24%
Adverse Event
23%
Diseases
20%
Metastatic Carcinoma
19%
Nephrectomy
19%
Bone Density
19%
Immunotherapy
18%
Androgen
17%
Dasatinib
14%
Cancer Cell
13%
Kidney Cancer
13%
Docetaxel
13%
Doxorubicin
13%
Vasculotropin
13%
Sunitinib
13%
Surgery
13%
Malignant Neoplasm
12%
Imatinib
12%
Ifosfamide
12%
Zoledronic Acid
12%
Methotrexate
12%
Gemcitabine
12%
Neuroendocrine Tumor
12%
Epirubicin
12%
Gastrointestinal Stromal Tumor
12%
Targeted Therapy
12%
Recurrent Disease
12%
Recurrence Free Survival
12%
Leiomyosarcoma
12%
Disease Free Survival
12%
Arm
12%